Viruses, e.g. bacteriophages and compositions thereof and preparation or purification thereof (C12N7)

Attenuated virus strain - biological preparation for cucumber plants protection against pathogenic strains of cucumber green mottle mosaic virus // 2642321
FIELD: biotechnology.SUBSTANCE: invention relates to an attenuated strain of the cucumber green mottle mosaic virus.EFFECT: invention effectively protects cucumber plants against pathogenic strains of the cucumber green mottle mosaic virus.2 tbl, 3 ex

Hpv chimeric particle // 2642287
FIELD: biotechnology.SUBSTANCE: chimeric virus-like particle (VLP) of human papilloma virus (HPV), and method for its production and extraction, methods for prevention or treatment of HPV infection or cervical cancer, and for induction of an immune response in the patient, including the administration of proposed HPV VLP, as well as the application of the proposed HPV VLP in these methods and in production of pharmaceuticals to implement these methods, are proposed. The proposed chimeric HPV VLPS has a diameter of about 30 nm and contains a chimeric polypeptide HPV 16 L1/L2, which consists of a polypeptide HPV 16 L1, in which the peptide HPV 16 L2 from the amino acid residue 414 is inserted. The peptide contains from 13 to 26 amino acids. The amino acids of the inserted HPV 16 L2 peptide replace the corresponding amino acids of the HPV 16 L1 polypeptide. A method is also provided for the production of said HPV VLP in a plant in which successful assembly of small chimeric HPV VLPs, having a diameter of 30 nm, takes place.EFFECT: proposed group of inventions can be used in medicine for the prevention or treatment of HPV infection or in antitumor therapy for cervical cancer.28 cl, 32 dwg, 11 tbl, 3 ex

A n2269/vniizzh/2015 strain of type a aphtae epizooticae foot-and-mouth disease virus for control of antigenic and immunogenic activity and for manufacture of biopreparations for diagnosis and specific prevention of type a foot-and-mouth disease // 2640261
FIELD: biotechnology.SUBSTANCE: characterized strain is isolated from the sick cattle and obtained by successive passages on sensitive hetero- and homologous cell cultures and deposited in the collection of the FGBU "VNIIZZH" under the registration number strain VIA A2269/VNIIZZH/2015 (production), (control cattle), (control swine). The presented strain is reproduced in transplantable cultures of kidney cells of the Siberian mountain ibex (PSGK-30), IB-RS-2, VNK-21. During 17-24 hours of incubation, the virus yield in these cell cultures reaches the values of 6.75-7.75 lg TCD50/cm3. The presented virus strain can be used for control of the antigenic and immunogenic activity and for manufacture of biopreparations for diagnosis and specific prevention of type A foot and mouth disease.EFFECT: with high multiplicity of infection, causes CPD after 17-24 hours, maintaining the original characteristics when passaging in cell cultures for 5 passages.5 cl, 1 dwg, 7 tbl, 7 ex

Computer-optimized antigens with wide reactivity spectrum for influenza viruses of h5n1 and h1n1 // 2639551
FIELD: biotechnology.SUBSTANCE: recombinant influenza hemagglutinin (HA) polypeptide to elicit an immune response to the H5N1 influenza virus containing the amino acid sequence from residues 2-568 of SEQ ID NO: 1 encoding its nucleic acid containing the proposed polypeptide fusion protein and virus-like particle (VLP) to elicit a response to the H5N1 influenza virus, an expression vector containing the nucleic acid, and an isolated cell containing it, a composition and method for eliciting an immune response to the H5N1 influenza virus, and a method for immunizing a subject are proposed. The proposed group of inventions can be used in medicine for immunization against the H5N1 influenza virus.EFFECT: proposed protein, VLP, and compositions are capable of eliciting an immune response with a wide range of reactivity to the H5N1 influenza virus.19 cl, 8 dwg, 5 ex
ethod of obtaining live cultural attenuated vaccine for the prevention of varicella // 2637093
FIELD: medicine.SUBSTANCE: method of obtaining live cultural attenuated vaccine for the prevention of varicella includes infection with varicella-zoster virus strain of OKA diploid cells LEC-3 with the subsequent reproduction and the release of virus into cultural medium. Thereafter, at least one collection of the virus-containing liquid, the addition of a stabiliser and the preparation of the vaccine are carried out. The group of inventions also relates to the use of a strain of diploid LEC-3 cells for the production of a live cultural attenuated vaccine for the prevention of varicella. The use of diploid cells of strain LEC-3 with high adhesiveness to the surface of growth allows to obtain from 7 to 15 individual virus collections with a high content of extracellular vaccine Varicella zoster virus.EFFECT: obtaining extracellular virus Varicella zoster by individual collections from infected diploid cells LEC-3 using trisodium citrate provides increased harvest of Varicella zoster virus than in similar cultural models when used as a dispersant of trypsin.7 cl, 1 tbl, 3 dwg
Composition of agar coatings for determining machupo - bolivian hemorrhagic fever virus population concentration and structure with using method of negative colonies // 2634868
FIELD: pharmacology.SUBSTANCE: agar coating composition for identifying Machupo virus is proposed. The primary agar coating comprises: an amino acid vitamin complex (AVC), Earle solution, fetal calf serum, 5% sodium bicarbonate solution, demineralized water, 2.9% solution of 1-glutamine, antibiotics, bacto-agar "BacteriologCal" or "Bacto™ Agar ". The secondary agar coating contains: an amino acid vitamin complex (AVC), Earle solution, fetal calf serum, sodium bicarbonate, demineralized water, 0.1% solution of neutral red, a bacto-agar "Bacteriologi Cal" or "Bacto™ Agar".EFFECT: increasing the sensitivity of the Machupo virus detection method.3 tbl, 4 ex

E. coli strain - producer of isolated domain 1 of protective bacillus anthracis antigen in form of virus-like particles // 2633508
FIELD: biotechnology.SUBSTANCE: strain is derived from the protective Bacillus anthracis antigen by inserting the pTrPPA plasmids into the E. coli strain BL21 (DE3). The plasmid pTrPPA contains a T7 phage promoter that controls the expression of a fusion gene that is a product of the 142 T5-like phage DT57C gene, known as the tail-terminating protein (TrP) fused at the 3'-end with domain 1 of the protective B. anthracis antigen, which allows the proteolytic cleavage during transport of a toxin into the cytoplasm of the target cell to preserve the structural stability of the antigen, and is expressed in the form of virus-like particles.EFFECT: increasing the yield of the target product under optimal cultivation conditions, obtaining of the isolated domain 1 of the main protective antigen of anthrax in the form of virus-like particles, which facilitates its purification and potentially increases immunogenicity.6 dwg

Ecoli strain - producer of full-dimensional protective bacillus anthracis antigen in form of virus-like particles // 2633504
FIELD: biotechnology.SUBSTANCE: presented strain was derived from the protective Bacillus anthracis antigen by inserting the pGEM-TTPPAG plasmids into the E. coli strain BL21 (DE3). The plasmid pGEM-TTPPAG contains a T7 phage promoter that controls the expression of a fusion gene that is a full-length TTR bacteriophage DT57C gene (encodes the pb6 tail tube protein) fused at the 3'-end with the B. anthracis protective antigen gene and expressed in the form of virus-like particles. The obtained HPV, free of soluble cell protein, can be used as an antigen for immunization.EFFECT: increasing the yield of the target product under optimal cultivation conditions, obtaining the main protective antigen of the causative agent of the anthrax in the form of virus-like particles, which facilitates its purification and potentially increases immunogenicity.5 dwg, 3 tbl

A/swine/siberia/1sw/2016 swine influenza virus strain of h1n1-subtype for influenza virus diagnosis by hir and pcr and research of effectiveness of vaccines and anti-viral drugs in vitro and in vivo // 2631938
FIELD: medicine.SUBSTANCE: strain of A/swine/Siberia/1sw/2016 swine influenza virus of H1N1 subtype isolated from homogenate of porcine lung tissue in Western Siberia and deposited in the State Collection of Viruses on the basis of the Institute of Virology named after D.I. Ivanovsky FSUE "FNICEM named after N. F. Gamaleya "of the Ministry of Health of Russia under number 2803 is proposed. The proposed strain can be used to prepare an antigen-containing substrate and serum for serodiagnosis of the H1 subtype influenza in the hemagglutination inhibition reaction (HIR), and can also be used as a reference sample for test systems specificity evaluation by PCR.EFFECT: ability to assess the effectiveness of antiviral drugs against influenza.2 dwg, 3 tbl, 4 ex
Hsobiens-wt/gin/2015/kalidie-kindia-1022 strain of ebola zaire to obtain antigen used as component of immunoenzymometric test system for detection of g and m antibodies to virus of ebola // 2631937
FIELD: biotechnology.SUBSTANCE: presented strain of the Ebola virus Zaire H.sapiens-wt/GIN/2015/Kalidie-Kindia-1022 is isolated from the blood of a patient with Ebola fever during the epidemic in Guinea 2014-2015 by 3 consecutive passages in BALB/c suckling mice and 6 consecutive passages on the Vero cell culture and deposited in the state collection of the causative agents of viral infections and rickettsiosis of the FBIS SSC VB "Vector" under the registration number V-695.EFFECT: invention makes it possible to obtain an antigen.6 tbl, 6 ex
Strain of influenza virus a/black-headed gull/kamchatka/123/2013 h11n8-subtitle for use in influenza virus diagnosis by hir and pcr methods and study of effectiveness of in vitro and in vivo anti-viral preparations // 2631932
FIELD: biotechnology.SUBSTANCE: strain of the avian influenza virus A/black-headed gull/Kamchatka/123/2013 H11N8 subtype is proposed, isolated from the lake gull (Larus ridibundus) and deposited in the State collection of viruses on the basis of the Institute of virology n. D.I. Ivanovsky FSBI "FRCEM named. N.F. Gamaleia" of the Ministry of Health of Russia under the registration number 2783. The proposed strain can be used to prepare an antigen-containing preparation and serum for serodiagnosis of influenza H11-subtype in the hemagglutination inhibition reaction (HIR), and can also be used as a control reference strain H11 when performing diagnostic tests using the PCR method.EFFECT: with the help of the proposed strain, it is possible to evaluate the effectiveness of therapeutic and prophylactic preparations against influenza.4 tbl, 4 ex
Strain "shevchenko-2014" of rabbit hemorrhagic disease virus for preparing vaccines, diagnostic and therapeutic preparations // 2631925
FIELD: veterinary science.SUBSTANCE: invention relates to veterinary virology and biotechnology and concerns the strain of rabbit hemorrhagic disease virus, Caliciviridae family, genus Lagovirus. Presented strain is deposited under number 55 in autonomous noncommercial organization "Scientific Research Institute of diagnosis and prevention of human and animals diseases". Registration name of strain "Shevchenko-2014".EFFECT: invention can be used for preparing vaccines, diagnostic and therapeutic preparations in viral hemorrhagic disease in rabbits.1 cl, 5 tbl
Recombinant of vv-gmcsf / lact-dgf virus of osvovicine, of only-colic activity and producing secretable chimeric white, containing from granulocyte-macrophagal colonistimulating human factor and oncotoxic protein of lactaptin // 2630672
FIELD: biotechnology.SUBSTANCE: recombinant strain has targeted oncolytic activity and produces a secreted chimeric protein consisting of human GM-CSF and lactaptin (GMCSF/lact). The strain VV-GMCSF/lact-dGF is constructed on the basis of the L-IVP strain of the vaccinia virus, which contains deletions of fragments of viral thymidine kinase and growth factor genes. The transgene of the chimeric protein GMCSF/lact is incorporated into the deletion region of the thymidine kinase gene, which includes the GM-CSF gene adjuvant, which is linked through a flexible GlyGlyGlySer linker to the oncotoxic peptide lactaptin. The claimed strain has a virulence decreased by more than 100-fold as compared to the initial L-IVP strain, as well as a high targeted oncolytic activity against human tumor cells of various genesis. The strain was deposited in the State Collection of the causative agents of viral infections and rickettsiosis of the SSC VB Vector under the registration number V-711 (18.04.2016).EFFECT: invention provides additional attenuation of the VACV virus against normal cells and enhances its lytic activity against cancer cells, and can also be used in biotechnology.8 dwg, 3 tbl, 6 ex
New virus of pig reproductive-respiratory syndrome (prrsv) of korean type // 2630306
FIELD: biotechnology.SUBSTANCE: vaccine composition is proposed to prevent pig reproductive-respiratory syndrome of the Korean type, containing a virus of the pig reproductive-respiratory syndrome (PRRS) of the Korean type (KTSS access number is 12096 BP) in the number from 2×105 up to 2×107 PFU/ml as an effective ingredient, method for Korean type PRRS prevention using such a vaccine, a Korean type PRRS virus diagnostic kit, and a Korean type PRRS virus detection method. The Korean type PRRS virus JW-BPPCC (KCTC 12096 BP) is isolated in Korea and differs from North American and European strains.EFFECT: inventions allow to prevent Korean type PRRS and provide specific diagnosis of Korean type PRRS virus infection.8 cl, 8 dwg, 19 tbl, 8 ex

Attenuated influenza vectors for the prevention and/or treatment of infectious diseases, as well as for cancer treatment // 2628690
FIELD: biotechnology.SUBSTANCE: attenuated influenza A viruses and, vectors on their basis and pharmaceutical compositions containing them are presented. The characterized attenuated influenza A virus, inducing a cross-protective response against influenza A and B virus, contains a chimeric NS fragment comprising a truncated reading frame of NS1 protein and a heterologous sequence of Nep protein gene, derived from a subtype of influenza A virus different from the subtype of said attenuated influenza A virus.EFFECT: invention can be used to prevent or treat infectious diseases, in particular influenza, as well as for the treatment of cancer.48 cl, 6 dwg, 3 tbl, 7 ex

Cats calicivirus ashley virus strain for study of drug antiviral activity related to cats calicivirus // 2628096
FIELD: biotechnology.SUBSTANCE: ashley strain off cats calicivirus, deposited in FBIS SSC VB Vector under the number V-697 is obtain, having stable infectious activity, adapted to the transplanted cell cultures.EFFECT: strain can be used to study the antiviral activity of drugs against cats calicivirus.6 dwg, 4 ex
Identification method for a and b versions of human herpes virus 6 // 2627607
FIELD: biotechnology.SUBSTANCE: invention relates to the clinical laboratory diagnosis of virus infections, and may be used for genotyping herpes virus 6 (HHV-6). The method enables to determine one-nucleotide polymorphisms specific for HHV-6A and HHV-6B in the U67 HHV-6 gene via real-time PCR using primers HHV6F 5'-CGGATACAGTAAGACGGGATAT-3' and HHV6R 5'-ACGTAAGCTTGCACAATGC-3' and two fluorescently labeled probes HHV6AZ F1-GCAATAGATTTGAGAACGCGCGGCAT-Q1 and HHV6BZ F2-GCAATAGATTCGGAAATGCGGCAT-Q2, where the presence of HHV-6A or HHV-6B is indicated when the exponential accumulation of the fluorescence signal is registered in the respective probes channels. The invention may be used for genotyping herpes virus 6 (HHV-6).EFFECT: rapid and reliable identification of viruses HHV-6A and HHV-6B.2 dwg, 1 ex
Vaccine influenza virus a/17/south africa/2013/01 (h1n1)pdm09 for production of live intranasal influenza vaccine for adults and children // 2627188
FIELD: biotechnology.SUBSTANCE: submitted strain A/17/South Africa/2013/01 (H1N1)pdm09 is a reassortant obtained by crossing of wild virus A/South Africa/3626/2013 (H1N1)pdm09 with virus A/Leningrad/134/17/57 (H2N2) - donor of attenuation, harmless to humans. The strain of live influenza A/17/South Africa/2013/01 (H1N1)pdm09 is characterised by a set of symptoms: antigenic specificity of the epidemic virus A/17/South Africa/3626/2013 (H1N1)pdm09, temperature sensitivity and cold adaptation, harmless to laboratory animals, which correlates with human attenuation. The reassortant has inherited the genes coding surface virus antigens - hemagglutinin (HA) and neuraminidase (NA) from the epidemic parent virus, and six genes coding internal non-glycosylated proteins from the attenuation donor.EFFECT: strain can be used in practical health care to prevent the incidence of influenza in adults and children.5 tbl
Reassortant strain of rn2/66-human a (h7n2) influenza virus for neuraminidase antibodies identification in case of influenza infection and vaccination // 2625024
FIELD: biotechnology.SUBSTANCE: diagnostic strain of RN2/66-human A (H7N2) influenza virus was obtained by crossing the equine influenza A/horse/Prague/1/1956(H7N7) virus with the cold-adapted vaccine strain A/17/California/66/395(H2N2) based on the attenuation donor A/Leningrad/134/17/57(H2N2). The strain contains the neuraminidase of the influenza virus subtype N2 A/California/1/1966 (H2N2) and influenza A/horse/Prague/1/1956 (H7N7) hemagglutinin. The RN2/66-human A(H7N2) strain actively multiplies in developing chick embryos at the optimum temperature of 33°C, which allows to accumulate viral material for subsequent purification and concentration. The RN2/66-human A (H7N2) strain can be used for solid-phase inhibition of neuraminidase activity to analyse background values of serum antibodies to influenza neuraminidase N2 in the human population and their changes as a result of infection/vaccination.EFFECT: improved strain properties.2 dwg, 1 tbl, 2 ex

Constructs of recombinant nonpathogenic marek's disease virus coding antigens of infectious laryngotracheitis virus and newcastle disease virus // 2624037
FIELD: biotechnology.SUBSTANCE: inventions relate to recombinant nonpathogenic Marek's disease virus (rMDVnp) representing a recombinant herpesvirus of turkeys (rHVT) and to the vaccine containing such virus and to the way of protecting hens from infectious laryngotracheitis virus (ILTV) and Newcastle disease virus (NDV). The presented virus contains the first nucleic acid inserted in the first unnecessary region of rMDVnp genome and the second nucleic acid inserted in the second unnecessary region of rMDVnp genome. The first nucleic acid comprises of a nucleotide sequence coding gD and gI ILTV proteins. The second nucleic acid contains a nucleotide sequence coding a Newcastle disease virus fusion protein (NDV F). The first unnecessary region and the second unnecessary region either are one and the same unnecessary region, or the first unnecessary region is a US2 region and the second unnecessary region is a UL7/8 region.EFFECT: inventions allow for obtaining a stable means of protection from ILTV and NDV.10 cl, 2 dwg, 5 tbl, 6 ex

Viral particle released after infection of human cytomegalovir (hcmv) of mammals cells, containing fusion protein, and its application // 2623172
FIELD: biotechnology.SUBSTANCE: invention relate to the virus particle is released after infection of human cytomegalovirus cells (HCMV), its use in the prevention or treatment of disease by the formation of neutralising antibodies against at least one antigenic heterologous peptide or by induction of CD8+T-lymphocyte response against such heterologous peptide and a vaccine comprising such a viral particle. The characterized viral particle is surrounded by a lipid membrane in which viral glycoproteins are shipped and contains neither viral DNA nor capsids. The particle comprises a fusion protein comprising one or several parts T-cell antigen pp65 and at least one heterologous peptide, and wherein at least one heterologous peptide amino acid incorporated at position W175 ot A534 of the amino acid sequence of T-cell antigen pp65.EFFECT: increased efficiency of application.23 cl, 5 dwg, 5 ex

Recombinant stain of vacδ6 vaccinia virus with broken genes of viralence c3l, n1l, j2r, a35r, a56r, b8r for the production of live cultural attenuated vaccine against natural smallpox and other orthopoxviral human infections // 2621868
FIELD: biotechnology.SUBSTANCE: recombinant strain of VACΔ6 vaccinia virus with broken genes C3L, N1L, J2R, A35R, A56R, B8R on the basis of cloned vaccinia virus (L-IVP strain). The proposed strain is deposited in State Collection of causative agents of viral infections, rickettsiosis of the SBSI of the SSC VB Vector with registration No. V-696 and is designed to produce a bladeless, attenuated live culture vaccine against the natural smallpox and other orthopoxviruses with enhanced immunogenic and protective activity.EFFECT: proposed recombinant strain can be used in medicine to produce a vaccine against natural smallpox and other human orthopoxviral infections.7 dwg, 2 tbl, 13 ex

Recombinant strain of vv-gmcsf-s-lact vaccinia virus, with oncolytic activity, producing granulocytor-macrophagal colony-stimulating human factor and secreted form of lactaptin oncotoxic protein // 2621861
FIELD: biotechnology.SUBSTANCE: characterised recombinant strain VV-GMCSF-S-Lact is constructed on the basis of the vaccinia virus L-IVP strain, containing deletions of fragments of viral thymidine kinase and growth factor genes with integrated granulocyte-macrophagal colony-stimulating factor (GM-CSF) with structure corresponding to human GM-CSF matrix RNA cDNA in the central part of the viral thymidine kinase gene; and the secreted S-Lact lactaptin gene, encoding a human cappase-casein fragment of 23-134 a.o. with "stitching" to its N-terminus of the GM-CSF signal peptide (MWLQSLLLLGTVACSIS), in the left end region of the viral genome. The human GM-CSF gene is expressed under the control of the natural promoter P7.5k of the vaccinia virus and produces the secreted form of a biologically active human GM-CSF in mammalian cells. The S-Lact gene is expressed under the control of the synthetic VACV promoter P7.5synth and produces the secreted oncotoxic protein lactaptin.EFFECT: strain has targeted oncolytic activity against human breast cancer cells in vitro and in vivo and is deposited in SVC of viral infections pathogens and rickettsiosis of FBIS SSC VB Vector under the number V-690.6 dwg, 1 tbl, 5 ex
ethod of obtaining microencapsulated forms of live culture vaccine against seasonal and pandemic influenza for intranasal use // 2617051
FIELD: biotechnology.SUBSTANCE: method includes obtaining a substance of influenza virus, a simultaneous introduction of a hardener and charged water-soluble polyeloctrolyte in the virus-containing substance to reach the final concentration of the polyelectrolyte and hardener which does not cause a phase separation in the medication solution. Further, the microcapsules are produced resulting from a composite coacervation of the charged polyelectrolyte and the hardener with a formation of a complex by freezing the solution at a speed of 0.1-3.0°C per minute to the temperature which is lower than the glass transition temperature of amorphous phase remaining after the ice crystallization and freeze-drying of the final microcapsules. The substance of the influenza virus is produced with a specific activity of not less than 7.0 lg EID50/0.5 ml in a serum-free medium containing a proteolytic enzyme in the amount of 0.25-50.0 mcg/ml and soy peptone stabiliser in a concentration of (0.5-4.0) wt %. Stabilizing soy peptone additives and sucrose are added to the purified substance together with the polyelectrolyte and hardener. Carbopol is used as a polyelectrolyte and gelatose is used as a hardener at the following quantitative component content in the resulting liquid substance prior to microencapsulation: soy peptone - (0.007-0.015) g/0.5 ml; sucrose - (0.007-0.015) g/0.5 ml; gelatose - (0.007-0.015) g/0.5 ml; carbopol - (0.00005-0.0001) g/0.5 ml; liquid nutritional medium containing influenza virus with a titre of not less than 107.0 EID50. The rest is up to 0.5 ml.EFFECT: use of this method for producing live-culture influenza vaccine in microcapsules provides for a higher immunogenicity in intranasal application due to increasing the adhesion of microcapsules to nasal mucosa.3 cl, 6 ex, 1 tbl, 1 dwg
Vaccination against foot and mouth disease and method for its production and use // 2617043
FIELD: biotechnology.SUBSTANCE: vaccine includes a viral FMD antigen, aluminium hydroxide, saponin, and chitosan succinate sodium salt additionally used as an adjuvant,at the following component ratio, wt %: 0.25-0.75 of saponin, 0.5-1.5 of chitosan succinate sodium salt, 15.0-25.0 of aluminium hydroxide in glycol buffer with of pH 7-8.6, and FMD viral antigen - the rest. The group of inventions relates to a method for production of a vaccine against foot and mouth disease.EFFECT: application of this group of inventions allows to increase the target product immunogenicity during animal vaccination against the foot and mouth disease.5 cl, 9 ex, 1 tbl
ethod of detecting of cell culture contamination with viruses by immunoperoxidase method // 2614256
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Method of detecting contamination with viruses of cell culture by immunoperoxidase method is described, involving reaction of antigen with labelled antibodies in clean cell culture and accounting of reaction results by color density of formed complex under microscope. Wherein reaction uses tablets with analyzed cell culture, contaminated with diarrhoea virus, and after adding into tablet wells of 0.10–0.12 ml of specific homologous serum diluted by 1:64 – 1:128 it is incubated, washed, then 0.10–0.12 ml of anti-specific immunoenzymometric conjugate is introduced, consisting of peroxidase marked antibodies against globulins of cattle blood serum, it is incubated, washed, substrate mixture is introduced consisting of 5-aminosalicylic acid and hydrogen peroxide, and 30–40 minutes later results are accounted under light microscope by formation of brown color in virus-containing cells. Invention improves control system of cell lines latent contamination with viruses used in laboratory practice and biological industry.EFFECT: invention allows to prevent biological contamination and is extremely important stage in production of vaccines and diagnostic preparations; this method can be used for certification at absence of viruses in again coming cell cultures; invention is practically feasible, cheap method of monitoring of cell cultures for content of virus and may be recommended for extensive use both in scientific research and practical virological laboratories, and in production in making diagnostic preparations and vaccines.1 cl, 2 ex
ethod for production of recombinant pseudoadenovirus particles concentrate, expressing hemagglutinin gene of influenza a/california/07/2009(h1n1) // 2614127
FIELD: biotechnology.SUBSTANCE: method for production of recombinant pseudoadenovirus particles (RPAN) concentrate, expressing the hemagglutinin gene of influenza a/california/07/2009(H1N1) is proposed. The method comprises: obtaining of a production cell culture; preparation of disaggregated starting RPAN culture samples; single-round infection of the production suspension cell culture, thereby obtaining a RPAN-containing crude suspension, with subsequent cell mass precipitation by centrifugation and spent culture medium diverting; precipitated cell mass resuspension in lysis buffer, then one-time freezing followed by suspension thawing the slurry and RPAN separation from the disrupted cells successively by centrifugation, ultrafiltration, anion exchange chromatography, size exclusion chromatography, sterile filtration to yield a sterile pharmaceutical grade RPAN concentrate with high level ofchromatographic purity.EFFECT: method allows to obtain an increased yield of RPAN and a possibility to obtain a concentrate with high titers and chromatographic purity, that meets the quality of a pharmaceutical product suitable for industrial production of influenza vaccines.1 dwg, 1 tbl, 5 ex

Bacteriophages, phage peptides and methods for application thereof // 2614114
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and virology. Described is bacteriophage F510/08, comprising genome, which contains nucleic acid sequence SEQ ID NO: 4. Bacteriophage shows activity upon Pseudomonas aeruginosa. Invention also describes versions of pharmaceutical composition containing such bacteriophage, and methods of therapy for treatment and prevention of bacterial infection.EFFECT: presented group of inventions can be applied in medicine.23 cl, 327 dwg, 7 tbl, 7 ex
Bacteriophages production method // 2613423
FIELD: biotechnology.SUBSTANCE: method comprises culturing bacterial cells of host strain in the absence of extraneous microflora, phage lysate preparation and purification by precipitation and/or filtration. After 30-120 minutes after culturing initiation, at the optimum growth temperature for the culture of rapidly growing host strain, every 30-60 minutes, smears are made from the host strain culture from the surface of solid nutrient medium or from a liquid culture medium. The smears are stained with a solution of acridine orange in the final concentration of 0.001% to 0.02% or acridine yellow solution to the final concentration of 0.01% to 0.2%. The stained smear is microscoped in fluorescence microscope. Time is set for inoculating the mother bacteriophage at achievement in the stained smear of not less than 50% in relation to the total host strain cells proportion of orange acridine stained cells, fluorescing with orange or red shades, or the proportion of yellow acridine stained cells fluorescing with yellow or orange shades, at achevement of less than 10% in relation to the total host strain cells proportion of cells with non-uniform fluorescence that is paired pole adjoining cells in the form of rods with irregular or spherical cytoplasm fluorescent and spherical or ellipsoidal cells with slightly fluorescenting central section. Then mother bacteriophage is inoculated.EFFECT: stability of achieving high bacteriophage titer upon phage lysate production in a changing nutritive medium formulations, and increase in the range of variations of the indicator values of the host strain and bacteriophage culturing.11 ex

H1n1 influenza virus antigens with wide spectrum of activity, optimized using computer tools // 2612900
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and virology. Production of optimized HA polypeptides of influenza virus H1N1 is described, causing immune response with wide spectrum of activity in relation to influenza virus H1N1 isolates. Optimized HA polypeptides were developed by series alignments of HA protein sequences and subsequent formation of consensus sequences based on structure of certain viruses H1N1 recovered from 1918 at 2011. Invention also describes composition, fused proteins and VLP containing HA polypeptides. Invention also describes sequence of nucleic acids, subjected to optimization of codons coding HA polypeptides and methods for inducing immune response against influenza virus in subject.EFFECT: disclosed group of inventions can be used in medicine.23 cl, 7 dwg, 3 ex

Virions of adeno-associated virus with optional capsid and methods of their use // 2611202
FIELD: medicine; biotechnology.SUBSTANCE: invention relates to biotechnology, virology, and medicine. Virions of adeno-associated virus (AAV) with optional capsid protein are presented, where AAV virions show high infection load of retinal cell at intravitreal injection compared with wild type AAV. Methods of delivering gene product in retinal cell of person and methods of treating eye diseases are also described.EFFECT: virions of adeno-associated virus with optional capsid and methods for using them are presented.24 cl, 25 dwg, 2 tbl, 3 ex
ethod of purifying filamentous bacteriophage m13 // 2610178
FIELD: biotechnology.SUBSTANCE: invention relates to a method of purifying filamentous bacteriophage M13. Method involves removal of bacterial mass after producing bacteriophage by first and second successive centrifugation followed by first purification of supernatant of bacteriophage by isoelectric precipitation with a reagent at pH 4.2, further third centrifuging and re-suspension of precipitate with bacteriophage, as well as repeated purification of suspension of bacteriophage by isoelectric precipitation with a reagent at pH 4.2 and fourth centrifugation of precipitate with bacteriophage to produce end product. For isoelectric precipitation agent used is sodium acetate buffer with pH = 4.2 in ratio to supernatant of bacteriophages of not less than 3:1 at first isoelectric precipitation, precipitate with bacteriophage after third centrifugation is re-suspended in TBS-buffer, and during repeated purification of re-suspended bacteriophage by isoelectric precipitation, sodium acetate buffer with pH = 4.2 is used in ratio to re-suspended bacteriophage of not less than 1:1. First and second centrifugation is carried out at 5,000 rpm and 12,000 rpm for 10 minutes at 20 °C, and third and fourth centrifugation is carried out at 10,000 rpm for 10 minutes at 4 °C.EFFECT: invention provides a higher level of sterility and purity of bacteriophage, especially in small quantities thereof using a simpler technique.1 cl, 7 tbl, 9 ex
ethod of prediction of recurrent vulvar cancer i and ii stage // 2608508
FIELD: medicine.SUBSTANCE: invention relates to medicine and concerns a method for prediction of relapse vulvar I and II stage. Proposed method consists in determining in tumour tissue a DNA of human papilloma virus by method of polymerase chain reaction. In the patients with stage I disease in the presence of virus, predict relapse by 57.3±0.3 months, in the absence of virus – through 36±0.12 months, in the patients with II stage of disease in the presence of virus occurrence of relapse is predicted through 48±0.2 months, while the absence of virus – through 27.1±0.08 months.EFFECT: invention can be used in gynecology for prediction of recurrent carcinoma of vulva.1 cl, 1 tbl, 4 ex
Attenuated strain "msc-2015 vniivvim" of african swine fever virus serotype viii for virology and molecular-genetic analysis // 2607791
FIELD: medicine.SUBSTANCE: invention relates to virology. Attenuated strain “SKA-2015 VNIIVViM” of african swine fever virus serotype VIII is disclosed. Strain is produced by intermittent passages and selection of virulent strain "Stavropol 01/08" in primary cell culture of LS and transplantable hybrid cell line A4C2/9k and it is deposited in State collection of strains of microorganisms GNU Rosselhozakademii VNIIVViM under No. 1847.EFFECT: strain "MSC-2015 VNIIVViM" can be used during virological, molecular-genetic research, studying immunogenesis of disease, development of diagnostic and vaccine preparations.1 cl, 4 tbl, 4 ex
ethods of producing viral particles with simplified surface proteins' glycosylation // 2607452
FIELD: biotechnology.SUBSTANCE: present invention relates to biotechnology. Method for production of influenza virus with monoglycosylated hemagglutinin-antigen (HA-antigen) is disclosed. Method involves cultivation of influenza virus, containing hemagglutinin-antigen in specific pathogen free (SPF) chicken egg with embryo with an effective amount of mannosidase inhibitor, concentration of which is sufficient for inhibiting of α-mannosidase I in the path of N-glycosylation followed by extraction of produced influenza virus. Further contact of extracted influenza virus with endoglycosidase (EndoH) leads to production of influenza virus, having monoglycosylated influenza virus HA-antigen.EFFECT: disclosed method enables to obtain influenza virus with monoglycosylated hemagglutinin-antigen (HA-antigen) with high yield using specific pathogen free (SPF) chicken eggs with embryo, and can be used for producing monoglycosylated hemagglutinin-antigen in production of vaccines.19 cl, 4 dwg, 4 ex

Viral vectors cleaning system // 2607044
FIELD: biotechnology.SUBSTANCE: disclosed is viral vector cleaning method. Method involves introduction of exogenous gene coding receptor and representing gene interest in packing cell line, followed by cells culturing, collection of supernatant containing viral vector particles carrying receptor on its outer shell. Subsequent supernatant incubation with ligand, connected with fragment, which can be extracted from supernatant, leads to ligand binding with receptor, as a result of which obtained ligand-viral vector complex can be extracted from supernatant to produce viral vector purified particles.EFFECT: proposed cleaning method is effective and provides high level of extraction, and can be used in biotechnology for viral vectors cleaning.15 cl, 3 dwg, 4 tbl, 6 ex
ethod of determining biological activity of measles, epidemic parotitis and rubella during production of associated preparations (versions) // 2606848
FIELD: biotechnology.SUBSTANCE: invention relates to medical biotechnology. Methods of determining biological activity of monocomponents in associated combined di-and trivaccines are disclosed, which contain vaccine strains of measles virus (l-16), epidemic parotitis (l-3) and/or rubella (Orlov).EFFECT: proposed methods make it possible to simplify technology of control of vaccine preparations and reduce cost of production of vaccines.3 cl, 5 tbl, 3 ex
ethod (versions) for capturing particles of interest from mixture // 2606609
FIELD: biotechnology.SUBSTANCE: present invention relates to a method for capturing virus-like particles of interest from a mixture containing destroyed plant cells. Method comprises use of an expanded bed of adsorbent containing resin material, balancing resin material at pH 6.0–8.0 and adding mixture to expanded bed of adsorbent for binding of virus-like particles. Degree of expansion of expanded bed is equal to 1–5. Further, adsorbent is washed. Virus-like particles are eluted from adsorbent.EFFECT: high purity of extracted particles, high process efficiency.17 cl, 9 tbl
Strain of nodular dermatitis virus of cattle dermatitis nodularis bovum, genus capripoxvirus to produce biopreparations for diagnosis and specific prevention of nodular dermatitis of cattle // 2606254
FIELD: veterinary science.SUBSTANCE: invention relates to veterinary virology and biotechnology and concerns strain of virus nodular dermatitis of cattle (VND CATTLE). Described strain is recovered from cows, patients of nodular dermatitis, and deposited in Collection of strains of FGBU "VNIIZT" under registration number - VND KRC/Dagestan/2015 (diagnostic). Strain is reproduced in cultures of cells YDK-04 and TY during 2÷3 days and accumulated in titre from 4.5 to 5.5 lg TCD50/cm3, preserves initial characteristics when passaging in cultures of cells YDK-04 and TY during 5 passages.EFFECT: obtained on its base antigen material can be used for making diagnostics and specific prevention of nodular dermatitis CATTLE.1 cl, 5 dwg, 6 tbl, 7 ex
Strain of influenza virus a/common muskrat/chany lake/226/05 h2n2-subtype for use in diagnostics of influenza virus by methods of rtga and pcr and studying efficacy of antiviral preparations in vitro and in vivo // 2606030
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and concerns influenza virus strain. Presented strain of virus of bird flu A/Common Muskrat/Chany Lake/226/05 H2N2-subtype, deposited in collection of microorganisms of Federal budgetary institution of science "State Research Centre for virology and biotechnology "Vector" under registration number V-623.EFFECT: invention can be used to study the efficacy of therapeutic and preventive preparations for influenza, for preparation of antigen-containing substrate and serum for serodiagnosis of influenza H2-subtype in RTGA, for use as a control reference sample when evaluating specificity of test systems based on polymerase chain reaction, as well as for studying efficacy of antiviral preparations in vitro and in vivo.1 cl, 4 tbl, 4 ex
Reassortant influenza virus strain a/17/silver gull/sarma/06/887 (h6n1) for preparing live influenza vaccine // 2606026
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and concerns influenza virus strain. Proposed a reassortant vaccine strain A/17/silver gull/Sarma/06/887 (H6N1). Strain is produced by crossing virus A/Silver gull/Sarma/51c/2006 (H6N1) with strain A/Leningrad/134/17/57 (H2N2) – donor of attenuation, harmless for adults and children. Strain A/17/silver gull/Sarma/06/887 (H6N1) actively propagates in developing chicken embryos at optimal temperature 33 °C, is characterised by heat sensitivity, cold adaptation and attenuation and immunogenicity for laboratory animals. Strain is deposited in the State collection of viruses FSBU of federal State Research Centre of epidemiology and microbiology of the honorary academician N.F. Gamaley of Ministry of health of the RF at № 2807.EFFECT: invention can be used for producing live influenza vaccine.1 cl, 1 dwg, 2 tbl, 2 ex

Vaccine influenza virus strain a/17/hongkong/2014/8296 (h3n2) for preparing live influenza intranasal vaccine for adults and children // 2606019
FIELD: medicine.SUBSTANCE: invention refers to medical virology and concerns influenza virus strain. Disclosed a vaccine strain A/17/Hongkong/2014/8296 (H3N2)-reassortant, produced by crossing "wild" virus A/Hongkong/4801/2014 (H3N2) with cold-adaptive heat-sensitive virus A/Leningrad/134/17/57 (H2N2) – attenuation donor, safe for humans. Presented strain A/17/Hongkong/2014/8296 (H3N2) actively propagated in chicken embryos at optimal temperature of 32 °C, characterized by temperature sensitivity and cold adaptation and safety for laboratory animals. Strain is deposited in the State collection of viruses FGBU "FNICEM nam. N.F. Gamalei" of the Ministry of Health of Russia, Institute of virology nam. D.I. Ivanovskogo under № 2818.EFFECT: invention can be used in practical health services for preventing influenza incidence in adults and children by a live influenza intranasal vaccine.1 cl, 1 dwg, 5 tbl

Influenza virus strain v/60/phuket/2013/26 for preparing live influenza intranasal vaccine for adults and children // 2605926
FIELD: medicine.SUBSTANCE: invention relates to virology. Disclosed is a vaccine strain V/60/Phuket/2013/26-reassortant, obtained by genetic reassortation of epidemic virus V/Phuket/3073/2013 with cold-adapted temperature-sensitive virus V/USSR/60/69 - attenuation donor, safe for humans. Strain of V/60/Phuket/2013/26 is characterised by temperature sensitivity and cold adaptation and safety for laboratory animals. Strain of V/60/Phuket/2013/26 comprises genes which code surface virus antigens of hemagglutinin (HA) virus and neuraminidase (NA), from an epidemic parent virus V/Phuket/3073/2013 and remaining six genes coding internal non-glycosylated proteins, from attenuation donor V/USSR/60/69.EFFECT: strain of V/60/Phuket/2013/26 can be used in medicine for preventing influenza incidence in adults and children in live influenza intranasal vaccine.1 cl, 4 tbl

Adapted pandemic influenza virus strains a/tomsk/273/2010-ma1(h1n1pdm09), a/tomsk/273/2010-ma2(h1n1pdm09) and a/tomsk/273/2010-ma3(h1n1pdm09) to assess the effect of antiviral drugs (versions) // 2605317
FIELD: medicine.SUBSTANCE: invention relates to general and medical virology and concerns influenza A virus. Obtaining new adapted versions of pandemic influenza A(H1N1)pdm09 strain to organisms of different laboratory animals, proposed three adapted versions of the pandemic influenza virus obtained from wild-type strain A/Tomsk/273/2010(H1N1pdm09) by multiple passing through lungs of experimental mice. Strain A/Tomsk/273/2010-MA1(H1N1pdm09) passed 7 passages through lungs of mice of line BALB/c, strain A/Tomsk/273/2010-MA2(H1N1pdm09) - 12 passages through lungs of mice of line C57BL/6z, and strain A/Tomsk/273/2010-MA3(H1N1pdm09) - 10 passages through lungs of mice of line CD1. All the above strains cause 100 % death rate among mice, to organisms of which they are adapted. Strain A/Tomsk/273/2010-MA1(H1N1pdm09) is high-fatal not only for mice, to the body of which it was adapted (mice of line of BALB/c), but for mice of opposite line C57BL/6z causing among the last 100 % lethality.EFFECT: obtained strains can be used for studying of mechanisms of adaptation of viral pathogens to new host with evaluation of action of antiviral drugs in treating of influenza disease caused by pandemic VG A(H1N1)pdm09.3 cl, 2 dwg, 5 tbl, 5 ex

Vaccine influenza virus strain a/17/bolivia/2013/6585 (h1n1)pdm09 for preparing live influenza intranasal vaccine for adults and children // 2605314
FIELD: medicine.SUBSTANCE: invention refers to medical virology and concerns influenza virus strain. Characterized vaccine strain A/17/Bolivia/2013/6585 (H1N1)pdm09 - reassortant, produced by crossing "wild" virus A/Bolivia/559/2013 (H1N1)pdm09 with cold-adapted heat-sensitive virus A/Leningrad/134/17/57 (H2N2) - donor of attenuation, safe for humans. Strain A/17/Bolivia/2013/6585 (H1N1)pdm09 actively propagated in developing chicken embryos at optimal temperature of 32 °C, characterised by thermal sensitivity and cold adaptation and safety for laboratory animals. Reassortant deposited in State collection of viruses of FGBU "FNICEM nam. N.F. Gamalei" of the Ministry of health of Russia Research Institute of virology. D. I. Ivanovskogo under №2809.EFFECT: invention can be used in practical health services for preventing influenza incidence in adults and children.1 cl, 5 tbl

Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and use thereof // 2604815
FIELD: biotechnologies.SUBSTANCE: invention relates to biotechnology, virology and immunology. Novel adenovirus strains with an improved seroprevalence are described. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof, and polynucleotides encoding the polypeptides and fragments thereof. Also provided is a vector comprising the isolated polynucleotide according to the invention; adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention, and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. Invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.EFFECT: disclosed group of inventions can be used in medicine.17 cl, 11 dwg, 4 tbl, 6 ex

Strain a n2166/krasnodarskiy/2013 murrain virus aphtae epizooticae type a for antigenic and immunogenic activity and to produce biopreparations for diagnosis and specific prevention of murrain type a // 2604200
FIELD: veterinary science.SUBSTANCE: invention relates to veterinary virology and biotechnology and concerns new murrain virus strain epizooticae type A fam. Picornaviridae, genus Aphtovirus, which is deposited in collection of FGBU “VNIISZH” under registration number murrain strain 2166/Krasnodarskiy/2013 (production, control of cattle). Presented strain is reproduced in primary trypsinated monolayer swine kidney cell culture (KC), passaged siberian mountain goat kidney cell cultures (PSGK-30), VHK-21 and IB-RS-2. During 18÷24 h of incubation virus yield in said cell cultures reaches 6.0÷7.33 lg TCD50/cm3. Multiplicity of infection (1÷10 TCD/cell) causes CPP after 5 hours, maintaining initial characteristics, when passaging in cell cultures throughout 5 passages.EFFECT: presented strain may be used for antigenic and immunogenic activity and to produce biopreparations for diagnostics and specific prevention of murrain type A.1 cl, 6 tbl, 6 ex

Recombinant strain vv-gmcsf-lact of vaccinia virus, having oncolytic activity and producing granulocytic-macrophagal colony-stimulating factor and oncotoxic lactaptin protein // 2604187
FIELD: biotechnology.SUBSTANCE: invention relates to a recombinant strain of vaccinia virus (VV). Disclosed recombinant strain VV-GMCSF-Lact is constructed based on strain L-IVP vaccinia virus, containing a deletion of virus thymidine kinase gene fragments and growth factor, in areas which are built: gene of human granulocyte-macrophage colony-stimulating factor (GM-CSF), structure of which corresponds to DNA matrix RNA of human GM-CSF, in central part of virus thymidine kinase gene; and lactaptin gene coding fragment of human kappa casein 23-134 a.o., in left terminal area of viral genome. Human GM-CSF gene is expressed under control of natural promoter P7.5 k vaccinia virus and produces secreted form of biologically active human GM-CSF in cells of mammals. Lactaptin gene is expressed under control of synthetic promoter of vaccinia virus P7.5synth and produces oncotoxic recombinant lactaptin protein. Disclosed strain is deposited in State collection of agents of viral infections and rickettsial diseases of FBIS SSC VB “Vector” under number V-688.EFFECT: described strain has high oncolytic activity on human breast cancer cell and can be used in biotechnology.1 cl, 5 dwg, 4 ex

Gene therapy for neurodegenerative disorders // 2603740
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology. Disclosed is a self-complementary adeno-associated virus vector for treating motor neuron disorders such as spinal muscular atrophy, amytrophic lateral sclerosis, spinal bulbar muscular atrophy, spinal cerebellar ataxia, primary lateral sclerosis, and traumatic spinal cord injury. Also described are compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to brain and/or spinal cord.EFFECT: disclosed group of inventions can be used in medicine.16 cl, 17 dwg, 4 ex
ethod of producing bacteriophage // 2603730
FIELD: biotechnology.SUBSTANCE: invention relates to production of a bacteriophage. Disclosed method involves inoculation of bacterial cell suspension in the titre of 108-1012 CFU/ml on a dense nutrient medium with the layer thickness from 3 to 25 mm and cultivation with no foreign microflora, when the air layer thickness over the surface of the dense nutrient medium is from 5 to 50 mm and at optimum temperature for a host strain culture growth. In 30-120 minutes after the beginning of culturing every 30-60 minutes smears are taken from the surface of the dense nutrient medium, coloured with an intercalating dye and microscoped. Cultivation is stopped when reaching at least 10 % in relation to the total amount of cells of the host cell fraction strain with heterogeneous fluorescent cytoplasm staining. Then the obtained lawn of the host strain culture is inoculated with a mother bacteriophage in the titre of 107-1010 BFU/ml. Cultivated for 13-15 hours with no foreign microflora, at the air layer thickness over the surface of the dense nutrient medium from 5 to 50 mm and at optimum temperature for the bacteriophage strain culture growth. Obtained a phage lysate when suspending, sucked off the phage lysate into a sterile container and cleaned. Invention provides reaching a stable high titre of bacteriophage (1012-1014 BFU/ml) when producing phage lysates both at varying formulations of nutrient media and increasing the span variation of values of culturing the host strain and the bacteriophage.EFFECT: invention can be used in biotechnology for obtaining products containing bacteriophages.9 cl
 
2550861.
Up!